RBx11160 Phase II Dose Ranging Study RBx/MMV05-06
NCT00362050
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
255
Enrollment
OTHER
Sponsor class
Conditions
Plasmodium Falciparum Malaria
Interventions
DRUG:
Treatment with 3 dose groups of RBx11160 over 7 days
Sponsor
Medicines for Malaria Venture
Collaborators
[object Object]
[object Object]